XML 45 R31.htm IDEA: XBRL DOCUMENT v3.3.1.900
License and Collaboration Agreements (Tables)
 12 Months Ended
Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

 

 

 

 

 

Year Ended December 31,

 

Partner

 

Agreement

 

2015

 

 

2014

 

 

2013

 

AstraZeneca AB

 

MOVANTIKTM (NKTR-118)

and MOVANTIKTM fixed-dose

combination program (NKTR-119)

 

$

130,000

 

 

$

105,001

 

 

$

25,016

 

Roche

 

PEGASYS® and MIRCERA®

 

 

12,816

 

 

 

12,845

 

 

 

18,382

 

Baxalta Incorporated

 

ADYNOVATETM

 

 

10,694

 

 

 

10,258

 

 

 

1,702

 

Amgen, Inc.

 

Neulasta®

 

 

5,000

 

 

 

5,000

 

 

 

5,035

 

Bayer Healthcare LLC

 

BAY41-6551 (Amikacin Inhale)

 

 

1,919

 

 

 

4,717

 

 

 

15,293

 

Affymax, Inc.

 

OMONTYS®

 

 

—

 

 

 

—

 

 

 

7,149

 

Other

 

 

 

 

5,175

 

 

 

15,468

 

 

 

8,295

 

License, collaboration and

   other revenue

 

 

 

$

165,604

 

 

$

153,289

 

 

$

80,872